drugset / Trial / NCT00197834

Study of Depakote for Behavioral and Psychological Symptoms in Dementia

NCT00197834

Phase 1 Unknown 20 enrolled Hearthstone Alzheimer Care Abbott · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This prospective, naturalistic, open label study will test the hypothesis that Depakote is correlated with a reduction in elevated Cohen-Mansfield Agitation Index (CMAI) verbal and physical agitation and aggression scales over a 6-week period among patients with elevated scores on those scales, and that these positive results can be achieved with fewer side effects than with other agents. In addition, patients will be rated with respect to changes in the Clinical Global Impression (CGI) at baseline, week 1, 3, and 6 and the Neuropsychiatric Inventory (NPI) at baseline and week 6.

Timeline

Start
2004-03
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Divalproex Sodium Small molecule

Indications